(VIANEWS) – Shares of Arcturus Therapeutics (NASDAQ: ARCT) fell by a staggering 28.07% in 21 sessions from $22.91 at 2023-02-02, to $16.48 at 19:31 EST on Friday, following the last session’s upward trend. NASDAQ is jumping 1.97% to $11,689.01, after two sequential sessions in a row of gains.
Arcturus Therapeutics’s last close was $16.48, 47.53% under its 52-week high of $31.41.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc. operates as a late-stage clinical mRNA medicines and vaccines company. Its technologies include LUNAR lipid-mediated delivery; STARR mRNA Technology (samRNA); and mRNA drug substance. The company's pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis with partnered programs, including glycogen storage disease type III and hepatitis B virus. Its RNA therapeutics platforms can be applied in multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Its technologies are covered by its patent portfolio, including patents and patent applications issued in the U.S., Europe, Japan, China, and other countries. The company was founded in 2013 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $-3.55.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -72.46%.
Sales Growth
Arcturus Therapeutics’s sales growth is 1154.4% for the present quarter and 1235.8% for the next.
Moving Average
Arcturus Therapeutics’s worth is way below its 50-day moving average of $18.65 and below its 200-day moving average of $17.35.
Revenue Growth
Year-on-year quarterly revenue growth grew by 448.6%, now sitting on 51.5M for the twelve trailing months.
More news about Arcturus Therapeutics (ARCT).
